A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).

Ori Yellin, Robert Vescio(Royal Adelaide Hospital), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Edwin Kingsley(Comprehensive Cancer Centers of Nevada), James R. Berenson(Oncotherapeutics (United States)), Stephen J. Noga, Youram Nassir, Saad Jamshed(Unity Health System), Wael A. Harb, Ralph V. Boccia(Center for Cancer and Blood Disorders), Paul Berard(St. Vincent's Medical Center), Allen Lee Cohn(Rocky Mountain Cancer Centers), Hassan Ghazal(Mohamed I University)

Journal of Clinical Oncology

May 20, 2012

10.1200/jco.2012.30.15_suppl.e18558

Cited by 6

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

|Annals of Oncology|2020|1.5k

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

|The Lancet Oncology|2015|954

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

|Breast Cancer Research and Treatment|2017|761

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

|Journal of Clinical Oncology|2008|623